LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Lu, Dan ^a   Lian, Hong ^a   Zhang, Xiaojuan ^a   Shao, Haitao ^a   Huang, Lan ^b   Qin, Chuan ^b   Zhang, Lianfeng ^a,b  

^a BEIJING HOSPITAL   (China)

^b INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; INTERMEDIATE FILAMENT PROTEIN; LAMIN A/C; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; CASPASE; COLLAGEN; LAMIN A; LMNA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL LOSS; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; GENE; GENE LOCATION; GENE MUTATION; HEART MUSCLE CELL; LMNA GENE; MITOCHONDRION; MITOCHONDRION SWELLING; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PROTEIN SECRETION; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; GENETICS; HEART MUSCLE; HUMAN; METABOLISM; MUSCLE CELL; MUTATION;

MUS; MUS MUSCULUS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARDIOMYOPATHY, DILATED; CASPASES; COLLAGEN; ENZYME ACTIVATION; HUMANS; LAMIN TYPE A; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; MUSCLE CELLS; MUTATION; MYOCARDIUM;

EID: 78650165326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015167     Document Type: Article

References (45)

1. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL (2005) The nuclear lamina comes of age. Nat Rev Mol Cell Biol 6: 21-31.
2. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, et al. (2004) Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 113: 370-378.
3. Crisp M, Liu Q, Roux K, Rattner JB, Shanahan C, et al. (2006) Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol 172: 41-53.
4. Broers JL, Peeters EA, Kuijpers HJ, Endert J, Bouten CV, et al. (2004) Decreased mechanical stiffness in LMNA-/- cells is caused by defective nucleocytoskeletal integrity: implications for the development of laminopathies. Hum Mol Genet 13: 2567-2580.
5. Mounkes L, Stewart CL (2004) Structural organization and functions of the nucleus in development, aging, and disease. Curr Top Dev Biol 61: 191-228.
6. Worman HJ, Courvalin JC (2004) How do mutations in lamins A and C cause disease? J Clin Invest 113: 349-351.
7. Genschel J, Schmidt HH (2000) Mutations in the LMNA gene encoding lamin A/C. Hum Mutat 16: 451-459.
8. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, et al. (2003) Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 41: 771-780.
9. van der Kooi AJ, Bonne G, Eymard B, Duboc D, Talim B, et al. (2002) Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. Neurology 59: 620-623.
10. Sebillon P, Bouchier C, Bidot LD, Bonne G, Ahamed K, et al. (2003) Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 40: 560-567.
11. Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, et al. (2006) Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 354: 209-210.
12. Botto N, Vittorini S, Colombo MG, Biagini A, Paradossi U, et al. (2010) A novel LMNA mutation (R189W) in familial dilated cardiomyopathy: evidence for a 'hot spot' region at exon 3: a case report. Cardiovasc Ultrasound 8: 9.
13. Mestroni L, Taylor MR (2008) Lamin A/C gene and the heart: how genetics may impact clinical care. J Am Coll Cardiol 52: 1261-1262.
14. Hutchison CJ, Alvarez-Reyes M, Vaughan OA (2001) Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J Cell Sci 114: 9-19.
15. Wang H, Wang J, Zheng W, Wang X, Wang S, et al. (2006) Mutation Glu82Lys in lamin A/C gene is associated with cardiomyopathy and conduction defect. Biochem Biophys Res Commun 344: 17-24.
16. Sagelius H, Rosengardten Y, Hanif M, Erdos MR, Rozell B, et al. (2008) Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J Cell Sci 121: 969-978.
17. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, et al. (2005) Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 14: 155-169.
18. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL (2007) Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 21: 55-62.
19. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, et al. (2004) Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 109: 1284-1291.
20. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, et al. (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97: 4239-4244.
21. Feng JJ, Marston S (2009) Genotype-phenotype correlations in ACTA1 mutations that cause congenital myopathies. Neuromuscul Disord 19: 6-16.
22. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, et al. (2006) The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30: 604-610.
23. Jugdutt BI (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108: 1395-1403.
24. Wang Y, Herron AJ, Worman HJ (2006) Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet 15: 2479-2489.
25. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL (2005) Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 14: 2167-2180.
26. Stuurman N, Heins S, Aebi U (1998) Nuclear lamins: their structure, assembly, and interactions. J Struct Biol 122: 42-66.
27. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, et al. (2000) Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 342: 770-780.
28. Burke B, Stewart CL (2002) Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol 3: 575-585.
29. Hutchison CJ (2002) Lamins: building blocks or regulators of gene expression? Nat Rev Mol Cell Biol 3: 848-858.
30. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, et al. (2004) Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 113: 357-369.
31. Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, et al. (2008) Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol 44: 293-303.
32. Henriques-Pons A, de Oliveira GM (2009) Is the FAS/FAS-L pathway a promising target for treating inflammatory heart disease? J Cardiovasc Pharmacol 53: 94-99.
33. Wollert KC, Heineke J, Westermann J, Lüdde M, Fiedler B, et al. (2000) The cardiac FAS (APO-1/CD95) Receptor/FAS ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation 101: 1172-1178.
34. Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, et al. (2002) Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the FAS (CD95/Apo-1) receptor: FAS activation and apoptosis in hypoxic myocytes. Cardiovasc Res 54: 611-623.
35. Barac YD, Zeevi-Levin N, Yaniv G, Reiter I, Milman F, et al. (2005) The 1,4,5- inositol trisphosphate pathway is a key component in FAS-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res 68: 75-86.
36. Lee SD, Tzang BS, Kuo WW, Lin YM, Yang AL, et al. (2007) Cardiac FAS receptor-dependent apoptotic pathway in obese Zucker rats. Obesity (Silver Spring) 15: 2407-2415.
37. Anselmi A, Gaudino M, Baldi A, Vetrovec GW, Bussani R, et al. (2008) Role of apoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med (Hagerstown) 9: 227-232.
38. Bishopric NH, Andreka P, Slepak T, Webster KA (2001) Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 1: 141-150.
39. Gupta S (2001) Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 69: 2957-2964.
40. Narula J, Pandey P, Arbustini E, Haider N, Narula N, et al. (1999) Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A 96: 8144-8149.
41. Eichhorn EJ, Bristow MR (1996) Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94: 2285-2296.
42. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, et al. (1995) The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 27: 291-305.
43. Andrés V, González JM (2009) Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol 187: 945-957.
44. Juan F, Wei D, Xiongzhi Q, Ran D, Chunmei M, et al. (2008) The changes of the cardiac structure and function in cTnTR141W transgenic mice. Int J Cardiol 128: 83-90.
45. Rottman JN, Ni G, Khoo M, Wang Z, Zhang W, et al. (2003) Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice. J Am Soc Echocardiogr 16: 1150-1157.